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Postdexamethasone Plasma Cortisol and P-Endorphin 
Levels in Depression: Relationship to Severity of 
Illness 
James H. Meador-Woodruff, Roger F. Haskett, Leon Grunhaus, 
Huda Akil, Stanley J. Watson, and John F. Greden 
The hypothalamic-pituitaty+zdrenal (HPA) axis is dysregulated in many patients with 
depression, probably at all levels of the axis. To determine if HPA dysregulation is 
associated with severity of depression, we studied a group of 66 patients with major 
depressive disorder. Each patient underwent a pretreatment Dexamethasone Suppression 
Test, with plasma postdexamethasone cortisol determination at 8:OO AM, 4.90 PM, and 
1 I :00 PM. All three postdexamethasone cortisol levels were signtjkantly correlated with 
the Hamilton Rating Scale for Depression (HRSD) scores. We also examined the “profile” 
measures of mean, maximum, and minimum of the three cortisol values; again, all three 
were significantly correlated with HRSD scores. To evaluate associations between clinical 
severity and HPA dysregulation at the pituitary level, we studied a second group of 44 
patients with major depressive disorder. Each had postdexamethasone cortisol deter- 
minations at 4:OO PM and I I :00 PM as well as pre- and postdexamethasone P-endorphin 
determinations at 4:OO PM. The cortisol data from this group followed the same pattern 
as in the first sample, and there was a significant relationship between HRSD score and 
degree of P-endorphin nonsuppression as well. These results suggest that severity of 
depression is one of the determinants of dysregulation at both adrenal and pituitary levels 
of the HPA axis, accounting for IO%-20% of the observed variance. 
Introduction 
Many patients with major depressive disorder (MDD) develop state-related hypotha- 
lamic-pituitary-adrenal (HPA) axis dysregulation (Carroll et al. 1981). Initially, such 
dysregulation was studied primarily by measuring secretory output at the adrenal level 
(Carroll et al. 1981; Charles et al. 1981; Brown et al. 1985). Subsequently, it became 
possible to study this dysregulation at the pituitary level by measuring proopiomelanocortin 
(POMC) derived peptides by radioimmunoassay, specifically adrenocorticotrophic hor- 
From the Clinical Studies Unit for Affective Disorders and the Mental Health Research Institute, Department of Psychiatry. 
University of Michigan, Ann Arbor. MI. 
Supported in part by NIMH Grants 1 ROI-40216-01 (to J.F.G.) and MH 36168 (to S.J.W.) and by the Mental Health Research 
Institute, Department of Psychiatry, and the Theophile Raphael Fund at the University of Michigan Medical Center. 
Address reptittt requests to Dr. JZUII~S H. Meador-Woodruff, Department of Psychiatry, Mental Health Research Institute, 
University of Michigan Medical Center, 205 Washtenaw Place, Ann Arbor, MI 48109-0720. 
Received May 6, 1986; revised November 3, 1986. 
0 1987 Society of Biological Psychiatry 0006-3223/87/$03.50 
I138 BIOL PSYCHIATRY 
1987;22:1137-1150 
J.H. Meador-Woodruff et al. 
mone (ACTH) (Kalin et al. 1982; Nasr et al. 1983b; Pfohl et al. 1985; Sherman and 
Pfohl 1985) and P-endorphin (BE) (Matthews et al. 1982, 1986). Most recently, research 
efforts have begun to focus on hypothalamic releasing factors in depression, especially 
corticotropin releasing factor (CRF) (Chrousos et al. 1983; Gold et al. 1984; Holsboer 
et al. 1985). The majority of these studies have indicated that dysregulation probably 
occurs at all levels of the HPA axis in patients with MDD. 
When Carroll et al. (1981) reported the standardization of the Dexamethasone Suppres- 
sion Test (DST) in depression, a maximum postdexamethasone plasma cortisol value of 
greater than 5.0 kg/d1 was defined as a nonsuppressive response, and most subsequent 
studies have adopted this value as a cutoff point. This referent value was derived from 
studies on melancholic patients and control subjects in an effort to find a specific biological 
marker for melancholia. In later work studying pituitary hormones, some investigators 
(Matthews et al. 1982, 1986) have adopted a convention of categorizing postdexame- 
thasone responses as suppressive or nonsuppressive by using the patient as his own control. 
This within-subject type of control was instituted for both lack of an absolute standard 
level for normality of plasma peptide concentrations and for technical reasons related to 
peptide assay systems. In the present study, we have employed these established criteria. 
In addition, we have attempted to gain additional descriptive information by considering 
plasma cortisol and BE as continuously distributed variables. 
Many factors that influence DST responses have been identified. Age (Oxenkrug et 
al. 1983; Davis et al. 1984; Lewis et al. 1984), recent weight loss (Keitner et al. 1985; 
Krishnan et al. 1985b), antidepressant withdrawal (Dilsaver and Greden 1985), alcoholism 
(Kroll et al. 1983), the presence of delusions (Rudorfer et al. 1982), and number of past 
depressive episodes (Yerevanian et al. 1984; Lenox et al. 1985) have all been shown to 
effect postdexamethasone cortisol responses. In addition, technical factors, such as dex- 
amethasone dose (Brown et al. 1983), timing and frequency of samples (Goldberg 1980), 
and cortisol assay characteristics (Demers and Derek 1977; Meltzer and Fang 1983) can 
influence DST results. 
The influence of severity of depression on the cortisol response to the DST has been 
examined in several studies. These studies have categorized patients as either DST sup- 
pressors or nonsuppressors and have then compared various depression rating scale dif- 
ferences (Reus 1982; Sangal et al. 1984; Krishnan et al. 1985a), degree of endogeneity 
(Kumar et al. 1986), or severity of specific depressive symptoms (Nasr and Gibbons 
1983; Nasr et al. 1983a) between these two groups. The effect of severity of depression 
on HPA dysregulation at the pituitary and higher levels has not been addressed experi- 
mentally. We examined the influence of severity of depression on HPA axis functioning 
at both the adrenal and pituitary levels by studying postdexamethasone cortisol and BE 
responses. 
Methods 
Two groups of patients admitted to the Clinical Studies Unit (CSU) for Affective Disorders 
in the Department of Psychiatry of the University of Michigan were identified for this 
study. All patients admitted to the CSU undergo a comprehensive diagnostic evaluation, 
including several unstructured diagnostic interviews by psychiatrists, a structured inter- 
view using the Schedule for Affective Disorders and Schizophrenia (SADS) (Spitzer and 
Endicott 1975) by a trained research staff member, and a detailed family history and 
social assessment by a social worker, as well as a thorough physical and laboratory 
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evaluation. After this information is obtained, diagnosis is made by consensual agreement 
of involved clinicians, using Research Diagnostic Criteria (RDC) (Spitzer et al. 1977). 
Group I 
Sixty-six patients admitted to the CSU from 1976 to 1983 were identified. Inclusion 
criteria were: (1) patients met RDC (Spitzer et al 1977) for MDD; (2) patients were not 
psychotic; (3) patients underwent a DST (1 mg) at the end of a medication-free period 
of up to 2 weeks; (4) each patient had postdexamethasone plasma cortisol levels determined 
at 8:00 AM, 4:00 PM, and 11:OO PM; (5) patients had no identifiable technical exclusions 
(Carroll et al. 1981) that are known to invalidate DST results; and (6) written informed 
consent was obtained for participation in these research activities. 
After a medication-free period of up to 2 weeks, each patient underwent a DST, 
receiving 1 mg of dexamethasone orally at 11:30 PM. The following day, postdexame- 
thasone plasma samples were taken at 8:00 AM, 4:00 PM, and 11:OO PM. Cortisol was 
determined by a modification of Murphy’s (1967) competitive protein-binding technique. 
On the day of the DST, each patient was rated for severity of depression on the 17-item 
Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960); raters were blind to 
DST results. The interrater reliability of the HRSD is studied on the CSU every 6 months 
and has consistently fallen within 2 points. 
For analysis, patients were clustered into five subgroups (I-V) by HRSD scores: O-IO 
(n = 3). 11-1.5 (n = 8), 16-20 (n = 14), 21-25 (n = 23), and 26-40 (n = 18). The 
concept that patients diagnosed with MDD can have HRSD scores less than 15 requires 
some explanation. An RDC diagnosis of MDD is made if the patient has had the required 
symptom complex for a given period of time, but within the 2 months preceding diagnosis; 
HRSD scores in this study were obtained at the time of the DST, usually following 2 
weeks of medication washout. During this time, a given percentage of patients will begin 
to show clinical improvement, reflecting natural resolution of depressive symptoms. 
placebo or hospitalization effects, and other factors. They will continue to have and meet 
RDC for MDD, but may be beginning recovery from the episode; this phenomenon is a 
necessary occurrence to study the effect of severity of depression on a biological marker 
such as postdexamethasone cortisol levels. 
Selected demographic and clinical parameters known to potentially confound DST 
results (i.e., age, recent weight change) were examined for differences between these 
subgroups. For statistical comparisons, one-way Analysis of Variance (ANOVA) was 
performed for continuously distributed variables and the x2 test for categorical variables; 
because of possible difficulties interpreting the x2 statistic when expected cell frequencies 
are low, some analyses were reperformed following pooling of subgroups, as indicated 
in Tables 1 and 2. 
Postdexamethasone cortisol values were logarithmically transformed prior to statistical 
analysis to improve normality. Mean postdexamethasone cortisol values were calculated 
for each subgroup at each time point. We also examined the “profile” measures of 
maximum, minimum, and mean postdexamethasone cortisol values. The profile-maximum 
value is the value usually reported in studies on HPA axis dysfunction (i.e., the measure 
used to define “nonsuppression” of DSTs); it was calculated by taking the mean of the 
highest of the three postdexamethasone cortisol values for each patient within a subgroup. 
The profile-minimum value was obtained by taking the lowest postdexamethasone co&o1 
value for each patient and calculating the mean for each subgroup. This measure was 
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5 6 
18 12 xz = 5.70” NS 
I1 16 
12 2 x* = 12.82” CO.02 
46.3 k 2.77 47.3 +- 4.10 F = 1.33 NS 
4.29 I 0.93 2.80 + 0.85 F = 0.82 NS 
“Means + SEM. 
“Analyses were reperformed after pooling subgroups, due to difficulties associated with interpretation of tbe x’ statistic when expected 
cell frequencies are small. For sex, pooled subgroups were (I + II), III, IV, and V; x2 = 4.89, df = 3, p NS. For pohity, poled 
subgroups were (I + II), III, IV, and V; x2 = 10.2, df = 3. p < 0.02. 
intended to detect any HPA dysregulation that might persist even when cortisol levels 
are at their lowest point. The profile-mean value was calculated by taking the mean of 
each subgroup of the average postdexamethasone cortisol value for each patient. This 
parameter was intended to minimize measurement error as well as any intrinsic “noise” 
in the HPA system. Statistical comparisons between subgroups were performed using 
one-way ANOVA with linear contrasts; p < 0.05 was used to define significant between- 
subgroup differences. 
Group 2 
After the data from Group 1 were analyzed, a second, smaller group of 44 patients from 
198 1 to 1985 was identified, for whom both cortisol and BE data were collected. Inclusion 
criteria for these patients were the same as for Group 1, except that for these patients 
postdexamethasone plasma cortisol levels were measured at only 4:OO and 11:OO PM. The 
DST, HRSD scoring, and cortisol determinations were performed as outlined for the first 
group. In addition, plasma samples for immunoreactive BE determination were collected 
every 20 min between 3:30 and 4:30 PM on both the predexamethasone and postdexa- 
methasone days, for a total of four samples on each day. BE was determined in triplicate 
in each sample by a previously validated radioimmunoassay (RIA) that we have developed 
(Matthews et al. 1982, 1986; Cahill et al. 1983). The mean plasma BE level on each 
day was defined as the average of the four samples obtained from each patient on that 
day. 
For analysis, patients in this group were clustered into the same five subgroups (I-V) 
by HRSD scores: O-10 (n = 8), 11-15 (n = 8), 16-20 (n = ll), 21-25 (n = 9), and 
26-40 (n = 8). The clinical and demographic data (i.e., age, sex, recent weight change) 
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analyzed in Group 1 were similarly studied in this group. As before, postdexamethasone 
cortisol levels were logarithmically transformed to improve normality. Mean cortisol 
levels were calculated for each subgroup at the time points available for these patients 
(4:00 and I I:00 PM). The three profile measures were also calculated for these patients 
as described for the previous group. Statistical comparison of the subgroups was made 
using one-way ANOVA with linear contrasts; p < 0.05 was used to define significant 
between-subgroup differences. 
The relationship between BE and HRSD scores was studied by two methods. First, 
the percentage of each subgroup that showed nonsuppression of BE plasma levels fol- 
lowing dexamethasone was calculated. We operationally defined nonsuppression as non- 
overlap of the means +- SEM of the samples from the two study days. This method of 
studying BE suppression in MDD has been validated previously in both depressed patients 
and psychiatric controls (Matthews et al. 1982, 1986). Statistical comparison between 
subgroups was made using the x2 test. We also calculated a BE nonsuppression index 
(% ABE) for each patient by subtracting the postdexamethasone BE level from the 
predexamethasone BE level, dividing by the predexamethasone BE level, and multiplying 
by 100%. This result was then subtracted from 100. For patients who had no suppression 
of BE following dexamethasone, the % ABE was set equal to 100. The mean % ABE 
( ~SEM) was calculated for each subgroup, and comparison between subgroups was 
accomplished by one-way ANOVA with linear contrasts, with p < 0.05 defining sig- 
nificant between-subgroup differences. A direct comparison of actual BE levels would 
have been preferable, but because of the small number of subjects and the intrinsic day- 
to-day variability and noise in RIA systems, we believe this type of comparison has 
questionable validity. The % ABE was regarded as a better indicator, as we measured 
the samples from both days for each patient in the same assay on the same day. 
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Results 
Group 1 (Cortisol Only) 
Table 1 summarizes various clinical and demographic data for the five subgroups studied 
in Group 1. There were no significant differences in the previously reported DST-con- 
founding variables of age (Oxenkrug et al. 1983; Davis et al. 1984; Lewis et al. 1984), 
number of previous depressive episodes (Yerevanian et al. 1984; Lenox et al. 1985), or 
recent weight change (Keitner et al. 1985; Krishnan et al. 1985b) between the subgroups. 
Polarity (Zisook et al. 198.5), however, appeared to be a confounding variable, with 
significant (x2 = 12.82, df = 4, p < 0.02) between-subgroup composition differences. 
A comparison of mean cortisol values of unipolar and bipolar depressives in each of the 
five subgroups was made for each time point, as well as the three profile measures. No 
Figure I. Postdexamethasone cortisol levels as a function of Hamilton Rating Scale for Depression 
(HRSD) scores in 66 depressed inpatients (Group 1) for individual sampling times (8:OO AM, 4:00 
PM, and 1 I:00 PM) (upper panel) and the “profile” measures of minimum, mean, and maximum 
plasma cortisol levels (lower panel). Subgroup I, HRSD = O-IO; subgroup II, HRSD = I l-1.5; 
subgroup III, HRSD = 16-20; subgroup IV, HRSD = 21-25; subgroup V, HRSD = 26-40. 
The between-subgroup differences are significant for each (one-way ANOVA; p values shown on 
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significant differences (two-tailed r-test) were found, suggesting that differences in the 
composition of the subgroups with respect to polarity was not a confounding factor. 
The relationship between postdexamethasone cortisol values at each sampled time 
point and severity of depression (reflected by HRSD score) is summarized in the top 
panel of Figure 1. At 8:00 AM, a significant upward trend appears (F = 3.05, df = 4,61, 
p = 0.02; significant differences are found between subgroups I and III, I and IV, I and 
V, II and III, II and IV, and II and V), with values generally increasing from a mean of 
1.14 k 0.08 kg/d1 in the lowest HRSD subgroup to a mean of 8.28 ‘-t 2.14 kg/d1 in 
the highest HRSD subgroup. The trend at 4:00 PM is also highly significant (F = 4.33, 
df = 4,61, p < 0.004; significant differences are found between subgroups I and II, 1 
and III, I and IV, I and V, II and V, III and V, and IV and V), with mean plasma cortisol 
values increasing from 1.00 k 0.32 kg/d1 to 11.59 +- 1.98 kg/d1 from the lowest to 
highest HRSD subgroups. At 1l:OO PM, the increase in plasma cortisol, from 1.46 -+ 0.54 
p,g/dl to 10.37 k 2.17 Fg/dl from lowest to highest HRSD subgroups, is also highly 
significant (F = 3.73, df = 4,61, p < 0.009; significant differences are found between 
subgroups I and IV, I and V, II and V, III and V, and IV and V). 
The results of the comparison of severity of illness and postdexamethasone plasma 
cortisol levels for the three profile measures are shown in the lower panel of Figure 1; 
all three profile measures were found to be significantly related to HRSD scores. The 
progressive increase in profile-maximum from 1.69 t 0.39 kg/d1 to 13.81 t 2.40 p,g/dl 
from lowest to highest HRSD subgroup is significant (F = 4.09, df = 4,61, p = 0.005; 
significant differences are found between subgroups I and III, I and IV, I and V, II and 
V, III and V, and IV and V), as is the increase from 0.72 2 0.16 kg/d1 to 6.23 k 1.48 
+g/dl of the minimum-profile levels (F = 3.71, df = 4,61, p = 0.009; significant dif- 
ferences are found between subgroups I and III, I and IV, I and V, II and IV, and II and 
V). The mean-profile increase from 1.20 k 0.25 pg/dl to 10.08 2 1.89 kg/d1 is similarly 
highly significant (F = 4.49, df = 4,61, p = 0.003; significant differences are found 
between subgroups I and III, 1 and IV, I and V, II and IV, II and V, III and V, and IV 
and V). 
We reexamined this apparent trend to increased postdexamethasone cortisol as a func- 
tion of HRSD by calculating correlation coefficients for HRSD score versus log-trans- 
formed postdexamethasone cortisol values at each time point and for the three “profile” 
measures. All r values were significant (at 8:00 AM, r = 0.29, df = 64, p < 0.05; all 
other time points and profile values, r = 0.374.42, df = 64, p < 0.01). We also 
analyzed these data in the more conventional manner of categorizing patients as DST 
suppressors or nonsuppressors (maximum postdexamethasone cortisol level >5.0 pg/dl) 
and determining the mean HRSD scores for each group. The mean (+ SEM) HRSD score 
for the suppressor group was 18.9 t 1.4 (n = 27) and was 24.7 + 0.9 (n = 39) for 
the nonsuppressor group; this difference was highly significant (t = 3.67, df = 64, 
p = 0.0005). 
Group 2 (Co&sol and BE) 
Table 2 summarizes for this group the same clinical and demographic parameters studied 
for Group 1. There were no statistically significant differences among the five subgroups 
in age, sex, number of previous episodes, polarity, or recent weight change. A trend 
toward increasing age as HRSD score increased did not reach significance. 
Figure 2 (top panel) demonstrates the postdexamethasone cortisol concentrations for 
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Figure 2. Postdexamethasone cortisol levels are a function of Hamilton Rating Scale for Depression 
(HRSD) scores in 44 depressed inpatients (Group 2) for individual sampling times (4:00 and 11:OO 
PM) (upper panel) and the “profile” measures of minimum, mean, and maximum plasma cortisol 
levels (lower panel). Subgroup I, HRSD = O-JO; subgroup II, HRSD = 11-1.5; subgroup III, 
HRSD = 16-20; subgroup IV, HRSD = 21-25; subgroup V, HRSD = 2640. The between- 
subgroup differences are significant at 11 :OO PM (one-way ANOVA: p < 0.05). Bars are 2 SEM. 
the five subgroups at 4:00 and 1 I:00 PM. The same trend toward higher cortisol levels 
in subgroups with higher HRSD scores observed in Group 1 is apparent and is especially 
obvious if all of the subgroups except the second (HRSD = 1 I-15) are examined. The 
observed increase at 1l:OO PM of plasma cortisol from 1.68 -+ 0.44 pg/dl to 5.05 k 1.18 
pg/dl from the subgroup with the lowest HRSD score to that with the highest is significant 
(F = 2.87, df = 4,39, p < 0.05; significant differences are found between subgroups 
I and II, I and V, and III and V). The increase at 1l:OO PM from 2.05 k 0.76 kg/d1 to 
4.01 _’ 1.20 pg/dl fails to reach significance (F = 0.425, df = 4,39, p NS). 
The “profile” measures for plasma cortisol are also summarized in Figure 2 (lower 
panel). Again, a trend toward increasing plasma cortisol as a function of HRSD score is 
apparent, with the exception of the increase in the second subgroup (HRSD = 11-15). 
None of these trends, however, reached significance (ANOVAs, profile-minimum, 
F = 0.697; profile-maximum, F = 0.938; profile-mean, F = 0.865; for all three, 
df = 4,39, p NS). 
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The results of analyzing plasma BE levels as a function of HRSD score are presented 
in Figure 3. The parameter % ABE tended to increase from subgroups with low HRSD 
scores to those with high scores (Figure 3A). Thus, in patients with higher HRSD scores, 
plasma BE was IikeIy to suppress to a fesser degree following dexamethasone. This 
upward trend (from 31.3 t 6.1 to 70.4 it 10.0 from the Q-10 HRSD subgroup to the 
26-40 I-IRSD subgroup) is significant (io = 3.132, df = 4,39, p < 0.05; significant 
differences are found between subgroups I and II, I and IV, I and V, and III and IV). 
When these data were analyzed by determining the percentage of patients in each subgroup 
who showed nonsuppression of pIasma BE foilowing dexamethasone (Figure 3B) a sim- 
Figure 3. plasma @-endorphin (BE) response to dexamethasone as a function of Hamilton Rating 
Scale far Depression (HRSD) scores in 44 depressed inpatients (Croup 2). Subgroup I, HRSD = O-10; 
subgroup B, HRSD = 11-15; subgroup 111, HRSD = 16-20; subgroup IV, HRSD = 21-25; 
subgroup V, HRSD = 2640. (A) Percent ABE as a function of HRSD score. Percent ABE is a 
measure of degree of nonsuppression of p&ma BE from pre- to ~stdex~e~asone days, as defined 
in the text. The ~tween-sub~oup differences are s~gn~~cant (one-way ANOVA, p < 0.05). (8) 
Percentage of patients in a subgroup manifesting nonsuppression of BE as defined in the text. The 
between-subgroup differences are significant (x2, p < 0.05). 
J 
II II: III IST Y 
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ilarly significant (x2 = 9.799, df = 4, p < 0.05) phenomenon was observed. Patients 
with high HRSD scores were thus less likely to show a suppressive response to dexa- 
methasone, as defined in the Methods section. 
The increase in cortisol and BE indices in the second subgroup was an interesting 
observation, given the continuous increase of cortisol responses shown in the first group 
of patients presented. This phenomenon was accounted for by two outlying patients with 
low HRSD scores (11-15) but very high cortisol levels and little BE suppression. No 
reason for these two patients to be significantly different from their subgroup mean could 
be identified. If these two patients are deleted from the analyses, the mean values for the 
second subgroup fall between those of subgroups I and III for each parameter, thus 
appearing similar to those results found in the Group 1 analyses. 
As with the first group, we reexamined the cortisol data from this group of patients 
by calculating correlation coefficients between HRSD scores and log-transformed post- 
dexamethasone cortisol levels. The 1 I:00 PM, profile-mean and -maximum values were 
modestly, but significantly, related (r = 0.33-0.43, df = 42, p < 0.05), but the 4:oO 
PM and profile-minimum values failed to reach significance (r = 0.24-0.28, df = 42, 
p NS). This type of analysis minimizes the contribution of the previously mentioned 
outliers in subgroup II; the correlation coefficients for each measure were similar between 
Groups 1 and 2. We also calculated the mean HRSD scores for both cortisol and BE 
suppressors and nonsuppressors. The cortisol suppressor group had a mean HRSD score 
of 16.4 c 1.2 (n = 32), and the nonsuppressors 22.6 ? 3.2 (n = 11). Similarly, the 
BE suppressors and nonsuppressors had mean HRSD scores of 15.6 ? 1.6 (n = 26) 
and 2 1.6 + 1.7 (n = 18), respectively. Both of these differences are significant (cortisol, 
t = 1.79, df = 42, p < 0.05; BE, t = 2.53, df = 42,~ < 0.01). 
Though age and weight change were not significantly different between subgroups in 
either group, the suggestion of between-subgroup trends existed for each. Because of this 
fact, and because of previous reports identifying age (Oxenkrug et al. 1983; David et al. 
1984; Lewis et al. 1984) and weight loss (Keitner et al. 1985; Krishnan et al. 1985b) as 
confounding variables on HPA functioning, we performed Analyses of Covariance, using 
cortisol and % ABE, respectively, as dependent variables, with weight change and age 
as covariates. Although for several analyses the covariates (especially weight change) 
approached significance, significant main effects among subgroups persisted. Correlation 
coefficients were also calculated for both age and degree of recent weight change and 
log-transformed cortisol levels at each time point; for age, r ranged from 0.28 to 0.43, 
and for recent weight change, from - 0.35 to + 0.15. The total percentage of the variance 
among subgroups attributable to these covariates was thus estimated from correlation 
coefficients to be from 2% to 17% each. 
Discussion 
These data suggest that severity of depression in MDD is an important factor in HPA 
axis dysregulation at both pituitary and adrenal levels. Other factors, however, are also 
believed to influence HPA axis function; age (Oxenkrug et al. 1983; Davis et al. 1984; 
Lewis et al. 1984), recent weight loss (Keitner et al. 1985; Krishnan et al. 1985b), number 
of previous depressive episodes (Yerevanian et al. 1984; Lenox et al. 1985), psychosis 
(Rudorfer et al. 1982), and polarity (Zisook et al. 1985) have been reported as potential 
confounding variables when HPA dysregulation has been studied. In the present inves- 
tigation, it was possible to isolate severity of illness for study by controlling for these 
other factors. An important consideration derived from the current data, however, is that 
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severity of depression should be taken into account in all studies on HPA function in 
MDD because of its association with HPA axis dysregulation. 
Previous studies of postdexamethasone cortisol response and severity of depression 
have dichotomized patients into DST suppressors and nonsuppressors and have examined 
various rating scale or symptom profile differences between these two groups. Sangal et 
al. (1984) found that cortisol nonsuppressors had significantly higher ratings on the Correa 
Depression Scale and on a modified HRSD, though not on the full-scale HRSD. HRSD 
full-scale differences have been demonstrated between cortisol suppressors and nonsup- 
pressors in chronic pain patients (Krishnan et al. 1985a) and psychiatric inpatients (Reus 
1982). Nasr and Gibbons (1983) and Nasr et al. (1983a) found no total HRSD score 
differences between suppressors and nonsuppressors, although the severity of specific 
symptoms gleaned from the rating scales were found to differ between these two groups. 
Others have shown that cortisol suppressors and nonsuppressors have significantly dif- 
ferent severity of various depressive symptoms, such as sleep disturbance, diurnal vari- 
ation, agitation, and decreased libido (Brown and Shuey 1980; Reus 1982; Krishnan et 
al. 1985a). The present data agree with past studies that have shown that cortisol non- 
suppressors have significantly higher HRSD scores than suppressors. They also dem- 
onstrate that the postdexamethasone cortisol response may be a state-related measure of 
severity of depression. 
The relationship between postdexamethasone cortisol response and severity of depres- 
sion is striking, with a significant positive correlation for each sampling time and for the 
three profile measures in Group 1. The Group 2 cortisol results seem less striking; no 
intrinsic differences between the two study groups could be identified that might explain 
why the significant trends in Group 1 were not as apparent in Group 2. The similar Group 
2 measures might have reached significance if the sample size had been larger; the 
contribution of two outliers in the 1 l-15 HRSD subgroup was also a factor in the failure 
to reach significance, as noted in the Results section. Nevertheless, the five correlation 
coefficients between cortisol levels and HRSD scores performed on this group did approach 
or reach significance and were similar to those calculated for Group 1. The total amount 
of variance of postdexamethasone cortisol values attributable to HRSD scores in this 
study was estimated from correlation coefficients to be IO%-20% for both Groups 1 and 
2; severity thus appears to be one of the determinants of adrenal level HPA dysregulation 
in MDD, but other factors (i.e., age, recent weight loss) certainly contribute to this 
dysregulation as well. 
Inspection of Figures 1 and 2 reveals that the mean cortisol levels between the two 
groups in this study are appreciably different, with the levels in Group 1 being twice 
those in Group 2. The possibility of changes in diagnostic patterns seems remote. as all 
patients were evaluated within the same system. A more likely explanation for this 
discrepancy between the two groups is drift in the cortisol assay over time. We have 
found that the mean plasma cortisol levels from the time period that the patients in Groups 
1 and 2 were studied were 7.1 2 7.4 kg/d1 and 3. I -C 3.2 kg/d1 (? SD), respectively. 
It is striking that despite the possible drift of our assay over time, the same general trend 
of association between postdexamethasone cortisol levels and HRSD scores emerges from 
these two independent groups. 
Past investigators have shown that a percentage of patients with MDD demonstrate 
nonsuppression of several POMC products as compared to normal or psychiatric controls, 
specifically ACTH (Kalin et al. 1982; Nasr et al. 1983b) and BE (Matthews et al. 1982, 
1986). The present data suggest that the pituitary response to dexamethasone, as reflected 
by circulating BE, is also a state-related measure of severity of depression. The variable 
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‘3%~ ABE, reflecting actual degree of postdexamethasone nonsuppression, increased as 
HRSD score increased. A similar pattern emerged when these data were analyzed in the 
more traditional manner of classifying patients as BE suppressors or nonsuppressors 
(Matthews et al. 1982, 1986) and determining the percentage of each subgroup that was 
nonsuppressor. 
The possibility of antidepressant withdrawal contributing to the modest state-dependent 
relationship demonstrated here should be considered. Dilsaver and Greden (1985) have 
shown that the DST can be confounded by medication withdrawal effects. It could be 
that the more severely ill patients (high HRSD subgroups) could not be maintained off 
of medications as long as less severely ill patients, thus causing the observed cortisol 
differences between those patients with low and high HRSD scores. This seems unlikely, 
as there were no detectable between-subgroup differences of duration of drug withdrawal. 
Nonetheless, this possibility should be considered in this and any study involving severity 
of depression and biological variables. 
The HPA axis is an intricate system, with multiple levels of hormone release and 
feedback regulatory loops. The hypothalamus releases CRF, which effects the release of 
POMC-derived peptides (i.e., BE and ACTH) from the anterior lobe of the pituitary. 
These hormones, in turn, facilitate the release of glucocorticoids from the adrenal cortex. 
The driving force for CRF release is presumably input from other brain regions, including 
limbic structures. A number of neurotransmitters, including acetylcholine, serotonin, 
norepinephrine, gamma-aminobutyric acid, and opioid peptides, are postulated to have 
modulating effects on CRF release; there may well be a correlation between clinically 
determined severity of depression and the degree of disruption of various limbic neuro- 
transmitters, such as serotonin and norepinephrine. The relationship between severity of 
depression and degree of HPA axis dysregulation that we have demonstrated at the adrenal 
and pituitary levels probably reflects the degree of central (limbic) disturbance, which 
may also be related to severity of illness. Whether or not this observed dysregulation at 
more peripheral levels of the axis actually occurs at higher HPA levels is not known, but 
will presumably be determined as the ability to measure HPA function at the hypothalamus 
and above develops. 
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